Related Experiment Video
Updated: Apr 13, 2026
08:58
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
13.0K
Medical therapy for ulcerative colitis 2004.
1Department of Medicine and Clinical Pharmacology, Section of Gastroenterology and Nutrition, University of Chicago, Illinois 60637, USA. shanauer@uchicago.edu
Gastroenterology
|May 29, 2004
Summary
Management of ulcerative colitis evolves with ongoing debates on aminosalicylates and immunomodulation. This review covers recent clinical studies on current and novel therapies for ulcerative colitis.
Area of Science:
- Gastroenterology
- Clinical Medicine
- Pharmacology
Background:
- Ulcerative colitis (UC) management has seen limited new drug approvals in recent decades.
- Aminosalicylate formulations remain a cornerstone, but their optimal use is debated.
- Immunomodulatory therapies' long-term benefits in UC require further clarification.
Purpose of the Study:
- To review recent clinical studies on ulcerative colitis (UC) management.
- To explore advances and controversies in UC therapies, including aminosalicylates, corticosteroids, and immunomodulators.
- To discuss novel therapeutic approaches and chemoprevention strategies for UC.
Main Methods:
- Review of recent clinical studies and literature on ulcerative colitis (UC) management.
- Analysis of data on aminosalicylate therapy, corticosteroids, cyclosporine, and purine antimetabolites.
- Exploration of emerging therapies such as biologics and probiotics for UC.
Main Results:
- Ongoing evolution in UC management despite few new drug approvals.
- Continued debate on optimizing aminosalicylate use and immunomodulation benefits.
- Emerging data on biological therapies targeting cytokines and adhesion molecules for UC.
Conclusions:
- Recent clinical studies highlight evolving strategies in ulcerative colitis (UC) management.
- Advances include novel biological therapies and a re-evaluation of existing treatments.
- Further research is needed to optimize UC treatment and explore chemoprevention.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
667
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
667
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
712
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
712
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
666
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
666
01:26Peptic Ulcer Disease IV: Management
676
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
676
01:29Inflammatory Bowel Disease IV: Pharmacological Management
986
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
986
01:21Inflammatory Bowel Disease V: Surgical Management
881
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
881